Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses.
TLS
Tfh
Treg
neutrophils
tumor stroma
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
04
2022
accepted:
10
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Tertiary lymphoid structures (TLS) are ectopic lymphoid organs that have been observed in chronic inflammatory conditions including cancer, where they are thought to exert a positive effect on prognosis. Both immune and non-immune cells participate in the genesis of TLS by establishing complex cross-talks requiring both soluble factors and cell-to-cell contact. Several immune cell types, including T follicular helper cells (Tfh), regulatory T cells (Tregs), and myeloid cells, may accumulate in TLS, possibly promoting or inhibiting their development. In this manuscript, we propose to review the available evidence regarding specific aspects of the TLS formation in solid cancers, including 1) the role of stromal cell composition and architecture in the recruitment of specific immune subpopulations and the formation of immune cell aggregates; 2) the contribution of the myeloid compartment (macrophages and neutrophils) to the development of antibody responses and the TLS formation; 3) the immunological and metabolic mechanisms dictating recruitment, expansion and plasticity of Tregs into T follicular regulatory cells, which are potentially sensitive to immunotherapeutic strategies directed to costimulatory receptors or checkpoint molecules.
Identifiants
pubmed: 35874810
doi: 10.3389/fcell.2022.933113
pii: 933113
pmc: PMC9304551
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
933113Informations de copyright
Copyright © 2022 Rossi, Belmonte, Carnevale, Liotti, De Rosa, Jaillon, Piconese and Tripodo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Ann Transl Med. 2021 Aug;9(16):1332
pubmed: 34532469
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Immunol Rev. 2010 Jan;233(1):267-85
pubmed: 20193005
J Leukoc Biol. 2019 Feb;105(2):243-255
pubmed: 30387907
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Immunity. 2018 Oct 16;49(4):695-708.e4
pubmed: 30291027
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Cancer Res. 2009 Mar 1;69(5):2000-9
pubmed: 19244125
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188
Cell Rep. 2019 Nov 12;29(7):1848-1861.e6
pubmed: 31722202
Sci Immunol. 2020 Apr 10;5(46):
pubmed: 32276965
Cancers (Basel). 2011 Dec 28;4(1):1-10
pubmed: 24213222
Lancet. 1985 Jan 12;1(8420):75-7
pubmed: 2857027
Front Biosci. 2008 Jan 01;13:2674-85
pubmed: 17981742
Nature. 2021 Mar;591(7851):652-658
pubmed: 33588426
J Exp Med. 2009 Oct 26;206(11):2339-49
pubmed: 19808255
Front Immunol. 2016 Oct 03;7:401
pubmed: 27752256
Mod Pathol. 2018 Jun;31(6):910-922
pubmed: 29416107
Mol Cancer. 2021 Nov 20;20(1):150
pubmed: 34798898
Nature. 2021 Mar;591(7851):645-651
pubmed: 33589820
Cancer Immunol Res. 2017 Oct;5(10):898-907
pubmed: 28848053
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
J Exp Med. 2015 Nov 16;212(12):2115-31
pubmed: 26481684
Front Immunol. 2018 Dec 11;9:2909
pubmed: 30619273
Cardiovasc Res. 2014 Mar 1;101(3):434-43
pubmed: 24272771
Ann Oncol. 2019 Feb 1;30(2):219-235
pubmed: 30608567
Breast Cancer Res Treat. 2020 Apr;180(2):369-377
pubmed: 32034580
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cell. 1999 Oct 1;99(1):23-33
pubmed: 10520991
Front Immunol. 2021 Jul 29;12:689270
pubmed: 34394083
Nat Biotechnol. 2004 Dec;22(12):1539-45
pubmed: 15568019
Nature. 2014 Oct 23;514(7523):498-502
pubmed: 25341788
J Immunol. 2011 Jul 15;187(2):828-34
pubmed: 21666055
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Cancer Immunol Res. 2013 Jul;1(1):32-42
pubmed: 24777248
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Science. 1996 Mar 1;271(5253):1289-91
pubmed: 8638112
Immunity. 2014 Dec 18;41(6):1026-39
pubmed: 25526313
Immunity. 2017 Aug 15;47(2):349-362.e5
pubmed: 28801233
Immunol Res. 2019 Oct;67(4-5):416-423
pubmed: 31440888
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cancer Res. 2012 Nov 1;72(21):5473-82
pubmed: 22962270
J Clin Invest. 2014 Dec;124(12):5191-204
pubmed: 25347469
J Immunol. 2018 Jan 15;200(2):432-442
pubmed: 29311385
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):
pubmed: 34257155
Cancers (Basel). 2021 Jun 28;13(13):
pubmed: 34203549
Front Immunol. 2013 Jan 14;3:416
pubmed: 23335923
Cancer Cell Int. 2021 Oct 15;21(1):536
pubmed: 34654433
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Trends Immunol. 2014 Nov;35(11):571-80
pubmed: 25443495
Oncoimmunology. 2017 Apr 28;6(6):e1322238
pubmed: 28680760
Oncoimmunology. 2015 Jun 3;5(2):e1054598
pubmed: 27057426
BMC Clin Pathol. 2014 Aug 23;14:38
pubmed: 25177210
Cancer Res. 2021 Jun 1;81(11):2983-2994
pubmed: 33757978
Immunity. 2006 Oct;25(4):643-54
pubmed: 17045819
Front Immunol. 2017 Dec 19;8:1830
pubmed: 29312327
Clin Cancer Res. 2014 Apr 15;20(8):2147-58
pubmed: 24523438
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
J Exp Med. 2009 Nov 23;206(12):2593-601
pubmed: 19917776
Oncoimmunology. 2015 Sep 11;5(4):e1085147
pubmed: 27141376
Cancer Cell. 2016 Jul 11;30(1):120-135
pubmed: 27374224
Curr Opin Immunol. 2001 Apr;13(2):172-9
pubmed: 11228410
Immunity. 2015 Apr 21;42(4):607-12
pubmed: 25902480
Cancer Immunol Immunother. 2007 Sep;56(9):1459-69
pubmed: 17279413
Front Immunol. 2021 Mar 08;12:626776
pubmed: 33763071
J Immunol. 2003 Jun 1;170(11):5475-82
pubmed: 12759424
Oncoimmunology. 2015 Jun 1;4(12):e1051922
pubmed: 26587322
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Clin Cancer Res. 2017 Jan 1;23(1):250-262
pubmed: 27354470
Lancet Oncol. 2017 Jan;18(1):52-62
pubmed: 27964843
Cell. 2000 Sep 1;102(5):553-63
pubmed: 11007474
Int Immunopharmacol. 2018 Aug;61:132-139
pubmed: 29870918
Oncoimmunology. 2021 Mar 29;10(1):1900508
pubmed: 33854820
Clin Cancer Res. 2015 Oct 1;21(19):4327-36
pubmed: 26429981
Nat Immunol. 2011 Dec 25;13(2):170-80
pubmed: 22197976
Cancer Med. 2021 Feb;10(4):1418-1430
pubmed: 33506656
Clin Cancer Res. 2019 Jun 1;25(11):3469-3470
pubmed: 31160495
J Immunol. 2005 Jan 1;174(1):21-5
pubmed: 15611222
Nat Commun. 2019 Feb 4;10(1):567
pubmed: 30718505
Front Immunol. 2017 May 17;8:563
pubmed: 28567040
Adv Cancer Res. 2015;128:197-233
pubmed: 26216634
J Exp Med. 1998 Oct 19;188(8):1493-501
pubmed: 9782126
Immunol Rev. 2019 May;289(1):31-41
pubmed: 30977192
Br J Pharmacol. 2008 Mar;153 Suppl 1:S241-6
pubmed: 17965753
Int Immunopharmacol. 2019 Mar;68:81-87
pubmed: 30616170
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Clin Exp Immunol. 2010 Jul 1;161(1):81-8
pubmed: 20408858
Nat Rev Immunol. 2006 Mar;6(3):205-17
pubmed: 16498451
Annu Rev Immunol. 2015;33:715-45
pubmed: 25861980
Cell Oncol (Dordr). 2019 Jun;42(3):343-356
pubmed: 30825183
J Exp Med. 2000 Sep 4;192(5):755-60
pubmed: 10974040
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Cell Mol Immunol. 2020 Jun;17(6):570-575
pubmed: 32415259
Open Access Maced J Med Sci. 2018 Oct 09;6(10):1824-1828
pubmed: 30455756
Immunity. 2021 Dec 14;54(12):2812-2824.e4
pubmed: 34861182
Aging (Albany NY). 2020 Feb 22;12(4):3451-3472
pubmed: 32087064
Clin Exp Metastasis. 2016 Oct;33(7):727-39
pubmed: 27449756
JCI Insight. 2019 Aug 13;5:
pubmed: 31408436
Cancer Cell. 2010 Aug 9;18(2):160-70
pubmed: 20708157
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):221-5
pubmed: 8552609
Front Immunol. 2016 Nov 08;7:477
pubmed: 27877173
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31689243
J Immunol. 2010 Jul 1;185(1):717-28
pubmed: 20525884
Mol Cancer. 2018 Nov 26;17(1):168
pubmed: 30477520
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Nat Immunol. 2015 Dec;16(12):1235-44
pubmed: 26502405
Cancer Res. 2018 Mar 1;78(5):1308-1320
pubmed: 29279354
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Nat Immunol. 2021 Aug;22(8):1052-1063
pubmed: 34168370
Oncoimmunology. 2020 Feb 17;9(1):1724763
pubmed: 32117589
Cancer Immunol Immunother. 2008 Jan;57(1):85-95
pubmed: 17605009
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Cancer Immunol Res. 2019 Feb;7(2):269-281
pubmed: 30563828
Oncoimmunology. 2017 Dec 18;7(2):e1378844
pubmed: 29416939
Front Immunol. 2021 May 14;12:675538
pubmed: 34054863
Nat Immunol. 2020 Mar;21(3):298-308
pubmed: 32066953
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
EMBO J. 2007 Jul 11;26(13):3191-202
pubmed: 17568779
Science. 2022 Jan 07;375(6576):eabf9419
pubmed: 34990248
Immunity. 2004 Nov;21(5):655-67
pubmed: 15539152
Cell Metab. 2020 Feb 4;31(2):422-437.e5
pubmed: 31883840
Immunity. 2015 Sep 15;43(3):579-90
pubmed: 26341400
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6546-E6555
pubmed: 29941600
Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19083-19089
pubmed: 31484769
Cancer Cell. 2022 Feb 14;40(2):201-218.e9
pubmed: 35090594
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Oncoimmunology. 2021 May 23;10(1):1929724
pubmed: 34104544
Nat Med. 2004 Sep;10(9):927-34
pubmed: 15311275
Front Immunol. 2021 Jun 10;12:679909
pubmed: 34177925
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147
Adv Cancer Res. 2015;128:263-307
pubmed: 26216636
Front Immunol. 2016 Nov 07;7:481
pubmed: 27872626
Cancer Immunol Res. 2017 Nov;5(11):1005-1015
pubmed: 28947544
J Exp Med. 2009 Jan 16;206(1):233-48
pubmed: 19139167
Cell Rep. 2015 Dec 29;13(12):2687-98
pubmed: 26711337
Hepatology. 2014 Nov;60(5):1494-507
pubmed: 24756990
Cancer Immunol Immunother. 2019 Nov;68(11):1733-1745
pubmed: 31598757
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
BMC Cancer. 2015 Mar 06;15:101
pubmed: 25884667
Front Immunol. 2016 Oct 03;7:407
pubmed: 27752258
Cell Rep. 2019 Feb 12;26(7):1854-1868.e5
pubmed: 30759395
J Exp Med. 2010 Aug 2;207(8):1791-804
pubmed: 20660615
Trends Immunol. 2012 Jun;33(6):297-305
pubmed: 22622061
Oncoimmunology. 2012 Sep 1;1(6):829-839
pubmed: 23162750
Immunol Rev. 2021 Jul;302(1):184-195
pubmed: 34060101
J Exp Med. 1999 Jan 4;189(1):159-68
pubmed: 9874572
Oncoimmunology. 2018 Nov 2;8(1):e1512458
pubmed: 30546950
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Nature. 2019 Mar;567(7749):479-485
pubmed: 30894752
Immunol Rev. 2020 Jul;296(1):24-35
pubmed: 32304104
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
Nat Immunol. 2017 Nov;18(11):1207-1217
pubmed: 28892469
Oncoimmunology. 2015 Apr 02;4(3):e974374
pubmed: 25949892
Immunology. 2021 Dec;164(4):677-688
pubmed: 34411302
J Exp Med. 1996 May 1;183(5):2367-72
pubmed: 8642347
Cancer Res. 2011 Sep 1;71(17):5678-87
pubmed: 21846823
Front Immunol. 2021 May 27;12:674375
pubmed: 34122434
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397